Cara ended 2023 with approximately $101 million in cash; runway extended into 2026
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CARA:
- Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
- Biotech Alert: Searches spiking for these stocks today
- Cara Therapeutics price target lowered to $2.50 from $7 at H.C. Wainwright
- Cara Therapeutics expects to end 2023 with $100M in cash
- Cara Therapeutics to discontinue clinical program in pruritus associated with AD